Coronavirus disease 2019 (COVID-19) is a global pandemic infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and abnormal, overactivated innate immunity and “cytokine storms” have been proposed as potential pathological mechanisms for rapid COVID-19 progression. Theoretically, asthmatic patients should have increased susceptibility and severity for SARS-CoV-2 infection due to a deficient antiviral immune response and the tendency for exacerbation elicited by common respiratory viruses. However, existing studies have not shown an expected prevalence of asthmatic individuals among COVID-19 patients. Certain aspects of type 2 immune response, including type 2 cytokines (IL-4, IL-13, etc.) and accumulation of eosinophils, might provide potential protective effects against COVID-19. Furthermore, conventional therapeutics for asthma, including inhaled corticosteroids, allergen immunotherapy (AIT), and anti-IgE monoclonal antibody, might also reduce the risks of asthmatics suffering infection of the virus through alleviating inflammation or enhancing antiviral defense. The interactions between COVID-19 and asthma deserve further attention and clarification.

冠状病毒病 2019 (COVID-19) 是由严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 引起的全球大流行性传染病，异常、过度激活的先天免疫和“细胞因子风暴”已被提出作为潜在的病理机制COVID-19 快速进展。从理论上讲，由于抗病毒免疫反应不足以及常见呼吸道病毒引起的恶化趋势，哮喘患者对 SARS-CoV-2 感染的易感性和严重程度应该会增加。然而，现有研究并未显示 COVID-19 患者中哮喘个体的预期患病率。2 型免疫反应的某些方面，包括 2 型细胞因子（IL-4、IL-13 等）和嗜酸性粒细胞的积累，可能对 COVID-19 提供潜在的保护作用。此外，哮喘的常规疗法，包括吸入皮质类固醇、过敏原免疫疗法 (AIT) 和抗 IgE 单克隆抗体，也可能通过减轻炎症或增强抗病毒防御来降低哮喘患者感染病毒的风险。COVID-19 与哮喘之间的相互作用值得进一步关注和澄清。